Given the transcriptional regulation ability and possible p53-modulating role of RFP, RFP might confer paclitaxel resistance to ovarian cancer cells through direct regulation of p53 function or transcriptional regulation of certain genes, such as miR-34c. This evidence concerns the gene TP53 and ovarian cancer.